Page 1330 - Williams Hematology ( PDFDrive )

1304 Part X: Malignant Myeloid Diseases Chapter 84: Polycythemia Vera 1305

208. Huang BT, Zeng QC, Zhao WH, et al: Interferon alpha-2b gains high sustained 239. Santos FP, Verstovsek S: Efficacy of ruxolitinib for myelofibrosis. Expert Opin Pharma-
response therapy for advanced essential thrombocythemia and polycythemia vera with cother 15(10):1465–1473, 2014.
JAK2V617F positive mutation. Leuk Res 38(10):1177–1183, 2014. 240. Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1
209. Steegmann JL, Requena MJ, Martin-Regueira P, et al: High incidence of autoimmune and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117–1127, 2010.
alterations in chronic myeloid leukemia patients treated with interferon-alpha. Am J 241. Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of rux-
Hematol 72(3):170–176, 2003. olitinib for myelofibrosis. N Engl J Med 366(9):799–807, 2012.
210. Quintas-Cardama A, Kantarjian HM, Giles F, et al: Pegylated interferon therapy for 242. Quintas-Cardama A, Vaddi K, Liu P, et al: Preclinical characterization of the selective
patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myelo-
Thromb Hemost 32(4 Pt 2):409–416, 2006. proliferative neoplasms. Blood 115(15):3109–3117, 2010.
211. Jabbour E, Kantarjian H, Cortes J, et al: PEG-IFN-alpha-2b therapy in BCR-ABL- 243. Garber K: JAK2 inhibitors: Not the next imatinib but researchers see other possibilities.
negative myeloproliferative disorders: Final result of a phase 2 study. Cancer 110(9): J Natl Cancer Inst 101(14):980–982, 2009.
2012–2018, 2007. 244. Mesa RA, Tefferi A: Emerging drugs for the therapy of primary and post essential
212. Samuelsson J, Hasselbalch H, Bruserud O, et al: A phase II trial of pegylated interferon thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs
alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, 14(3):471–479, 2009.
clinical and biologic effects, and impact on quality of life. Cancer 106(11):2397–2405, 245. Kralovics R, Teo SS, Li S, et al: Acquisition of the V617F mutation of JAK2 is a
2006. late genetic event in a subset of patients with myeloproliferative disorders. Blood
213. Samuelsson J, Mutschler M, Birgegard G, et al: Limited effects on JAK2 mutational 108(4):1377–1380, 2006.
status after pegylated interferon alpha-2b therapy in polycythemia vera and essential 246. Plo I, Nakatake M, Malivert L, et al: JAK2 stimulates homologous recombination and
thrombocythemia. Haematologica 91(9):1281–1282, 2006. genetic instability: Potential implication in the heterogeneity of myeloproliferative dis-
214. Kiladjian JJ, Cassinat B, Chevret S, et al: Pegylated interferon-alfa-2a induces complete orders. Blood 112(4):1402–1412, 2008.
hematologic and molecular responses with low toxicity in polycythemia vera. Blood 247. Nguyen HM, Gotlib J: Insights into the molecular genetics of myeloproliferative neo-
112(8):3065–3072, 2008. plasms. Am Soc Clin Oncol Educ Book 411–418, 2012.
215. Kiladjian JJ, Cassinat B, Turlure P, et al: High molecular response rate of polycythemia 248. Reuther GW: Recurring mutations in myeloproliferative neoplasms alter epigenetic
vera patients treated with pegylated interferon alpha-2a. Blood 108(6):2037–2040, 2006. regulation of gene expression. Am J Cancer Res 1(6):752–762, 2011.
216. Berlin NI, Wasserman LR: Polycythemia vera: A retrospective and reprise. J Lab Clin 249. Mascarenhas J, Roper N, Chaurasia P, et al: Epigenetic abnormalities in myeloprolifera-
Med 130(4):365–373, 1997. tive neoplasms: A target for novel therapeutic strategies. Clin Epigenetics 2(2):197–212,
217. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in 2011.
primary proliferative polycythaemia. Lancet 2(8102):1219–1222, 1978. 250. Skov V, Larsen TS, Thomassen M, et al: Increased gene expression of histone deacet-
218. Vongpatanasin W, Brickner ME, Hillis LD, et al: The Eisenmenger syndrome in adults. ylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Ann Intern Med 128(9):745–755, 1998. Leuk Lymphoma 53(1):123–129, 2012.
219. Thorne SA: Management of polycythaemia in adults with cyanotic congenital heart 251. Guerini V, Barbui V, Spinelli O, et al: The histone deacetylase inhibitor ITF2357 selec-
disease. Heart 79(4):315–316, 1998. tively targets cells bearing mutated JAK2(V617F). Leukemia 22(4):740–747, 2008.
220. Perloff JK, Marelli AJ, Miner PD: Risk of stroke in adults with cyanotic congenital heart 252. Amaru Calzada A, Todoerti K, Donadoni L, et al: The HDAC inhibitor Givinostat
disease. Circulation 87(6):1954–1959, 1993. modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F)
221. Di Nisio M, Barbui T, Di Gennaro L, et al: The haematocrit and platelet target in poly- myeloproliferative neoplasm cells. Exp Hematol 40(8):634–645 e10, 2012.
cythemia vera. Br J Haematol 136(2):249–259, 2007. 253. Andersen CL, McMullin MF, Ejerblad E, et al: A phase II study of vorinostat (MK-0683)
222. Marchioli R, Finazzi G, Specchia G, et al: Cardiovascular events and intensity of treat- in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol
ment in polycythemia vera. N Engl J Med 368(1):22–33, 2013. 162(4):498–508, 2013.
223. Prchal JT, Gordeuk VR: Treatment target in polycythemia vera. N Engl J Med 254. Rambaldi A, Dellacasa CM, Finazzi G, et al: A pilot study of the histone-deacetylase
368(16):1555–1556, 2013. inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative
224. Petitt RM, Silverstein MN, Petrone ME: Anagrelide for control of thrombocythemia neoplasms. Br J Haematol 150(4):446–455, 2010.
in polycythemia and other myeloproliferative disorders. Semin Hematol 34(1):51–54, 255. Hoffman R, Prchal JT, Samuelson S, et al: Philadelphia chromosome-negative mye-
1997. loproliferative disorders: Biology and treatment. Biol Blood Marrow Transplant 13(1
225. Storen EC, Tefferi A: Long-term use of anagrelide in young patients with essential Suppl 1):64–72, 2007.
thrombocythemia. Blood 97(4):863–866, 2001. 256. Rosenthal DS: Clinical aspects of chronic myeloproliferative diseases. Am J Med Sci
226. Gisslinger H, Gotic M, Holowiecki J, et al: Anagrelide compared with hydroxyurea in 304(2):109–124, 1992.
WHO-classified essential thrombocythemia: The ANAHYDRET Study, a randomized 257. Tefferi A, Mesa RA, Nagorney DM, et al: Splenectomy in myelofibrosis with myeloid
controlled trial. Blood 121(10):1720–1728, 2013. metaplasia: A single-institution experience with 223 patients. Blood 95(7):2226–2233,
227. Swerlick RA: Photochemotherapy treatment of pruritus associated with polycythemia 2000.
vera. J Am Acad Dermatol 13(4):675–677, 1985. 258. Devine SM, Hoffman R, Verma A, et al: Allogeneic blood cell transplantation following
228. Bircher AJ: Water-induced itching. Dermatologica 181(2):83–87, 1990. reduced-intensity conditioning is effective therapy for older patients with myelofibrosis
229. de Wolf JT, Hendriks DW, Egger RC, et al: Alpha-interferon for intractable pruritus in with myeloid metaplasia. Blood 99(6):2255–2258, 2002.
polycythaemia vera. Lancet 337(8735):241, 1991. 259. Anderson JE, Sale G, Appelbaum FR, et al: Allogeneic marrow transplantation for pri-
230. Foa P, Massaro P, Caldiera S, et al: Long-term therapeutic efficacy and toxicity of recom- mary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential
binant interferon-alpha 2a in polycythaemia vera. Eur J Haematol 60(5):273–277, 1998. thrombocytosis. Br J Haematol 98(4):1010–1016, 1997.
231. Ozturk A, Gunay A, Uskent N: Therapeutic efficacy of recombinant interferon-alpha in 260. Lussana F, Rambaldi A, Finazzi MC, et al: Allogeneic hematopoietic stem cell transplan-
polycythaemia vera. Acta Haematol 99(2):89–91, 1998. tation in patients with polycythemia vera or essential thrombocythemia transformed to
232. Verstovsek S, Kiladjian JJ, Grieshammer M, et al: Results of a Prospective, Randomized, myelofibrosis or acute myeloid leukemia: A report from the MPN Subcommittee of the
Open-Label Phase 3 Study of Ruxolitinib (RUX) in Polycythemia Vera (PV) Patients Chronic Malignancies Working Party of the European Group for Blood and Marrow
Resistant to or Intolerant of Hydroxyurea (HU): The RESPONSE Trial, abstract #7026. Transplantation. Haematologica 99(5):916–921, 2014.
American Society of Clinical Oncology (ASCO), Chicago, 2014. 261. Camos M, Cervantes F, Montoto S, et al: Acute lymphoid leukemia following poly-
233. Verstovsek S, Passamonti F, Rambaldi A, et al: A phase 2 study of ruxolitinib, an oral cythemia vera. Leuk Lymphoma 32(3–4):395–398, 1999.
JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refrac- 262. Higuchi T, Oba R, Endo M, et al: Transition of polycythemia vera to chronic neu-
tory or intolerant to hydroxyurea. Cancer 120(4):513–520, 2014. trophilic leukemia. Leuk Lymphoma 33(1–2):203–206, 1999.
234. Tartaglia AP, Goldberg JD, Berk PD, et al: Adverse effects of antiaggregating platelet 263. Shariff F, Harrison C: Polycythemia vera: Can we do better? Expert Opin Pharmacother
therapy in the treatment of polycythemia vera. Semin Hematol 23(3):172–176, 1986. 14(6):687–689, 2013.
235. Landolfi R, Marchioli R: European Collaboration on Low-dose Aspirin in Polycythemia 264. Hensley B, Geyer H, Mesa R: Polycythemia vera: Current pharmacotherapy and future
Vera (ECLAP): A randomized trial. Semin Thromb Hemost 23(5):473–478, 1997. directions. Expert Opin Pharmacother 14(5):609–617, 2013.
236. Mascarenhas JO, Cross NC, Mesa RA: The future of JAK inhibition in myelofibrosis and 265. Passamonti F, Malabarba L, Orlandi E, et al: Polycythemia vera in young patients: A
beyond. Blood Rev 28(5):189–196, 2014. study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica
237. Scherber R, Mesa RA: Future therapies for the myeloproliferative neoplasms. Curr 88(1):13–18, 2003.
Hematol Malig Rep 6(1):22–27, 2011. 266. Rozman C, Giralt M, Feliu E, et al: Life expectancy of patients with chronic nonleuke-
238. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with ruxolitinib versus best mic myeloproliferative disorders. Cancer 67(10):2658–2663, 1991.
available therapy for myelofibrosis. N Engl J Med 366(9):787–798, 2012.

Kaushansky_chapter 84_p1291-1306.indd 1305 9/21/15 11:11 AM